2022 ALS/MND (poster): Investigating the role of neuroinflammation in C9ORF72 ALS using stem cell models

/in , ,

View Poster:
2022 ALS/MND (poster): Investigating the role of neuroinflammation in C9ORF72 ALS using stem cell models

2024 AD/PD (poster): An assay platform to validate novel direct modulators of β-Glucocerebrosidase

/in , ,

View Poster:
2024 AD/PD (poster): An assay platform to validate novel direct modulators of β-Glucocerebrosidase

2023 AD/PD (poster): Development of a Cellular Platform to Study Lysosomal Functions in Neurodegeneration

/in , ,

View Poster:
2023 AD/PD (poster): Development of a Cellular Platform to Study Lysosomal Functions in Neurodegeneration

Martins et al; “The preclinical pharmacokinetics of Tolinapant—A dual cIAP1/XIAP antagonist with in vivo efficacy” Pharmacol Res Perspect, 2024

/in , , , ,

Martins et al; “The preclinical pharmacokinetics of Tolinapant—A dual cIAP1/XIAP antagonist with in vivo efficacy” Pharmacol Res Perspect, 2024

https://doi.org/10.1002/prp2.70030

 

2024 ENA (poster): Pulsatile Induction of the p53 Pathway by MDM2 Antagonist ASTX295 Shows an Enhanced Therapeutic Index in vivo

/in , , , , ,

View Poster:
2024 ENA (poster): Pulsatile Induction of the p53 Pathway by MDM2 Antagonist ASTX295 Shows an Enhanced Therapeutic Index in vivo

2024 ENA (poster): A Novel Small-Molecule CBP/p300 HAT Domain Inhibitor Demonstrates Potent In Vivo Activity and a Favourable Safety Profile in Preclinical Species

/in , ,

View Poster:
2024 ENA (poster): A Novel Small-Molecule CBP/p300 HAT Domain Inhibitor Demonstrates Potent In Vivo Activity and a Favourable Safety Profile in Preclinical Species

2024 ENA (poster): Targeting the Catalytic HAT Domain of CBP/p300 for the Treatment of Hormone-Dependent Breast and Prostate Cancers

/in , ,

View Poster:
2024 ENA (poster): Targeting the Catalytic HAT Domain of CBP/p300 for the Treatment of Hormone-Dependent Breast and Prostate Cancers

2024 ENA (poster): Identification of Biomarkers Predictive of Response to ASTX295, a Next-Generation MDM2 Antagonist, in Solid Tumors Carrying Wild-type p53

/in , , , , ,

View Poster:
2024 ENA (poster): Identification of Biomarkers Predictive of Response to ASTX295, a Next-Generation MDM2 Antagonist, in Solid Tumors Carrying Wild-type p53

Ramos et al; “Proteome-wide CETSA reveals diverse apoptosis-inducing mechanisms converging on an initial apoptosis effector stage at the nuclear periphery” Cell Reports, 2024

/in ,

Ramos et al; “Proteome-wide CETSA reveals diverse apoptosis-inducing mechanisms converging on an initial apoptosis effector stage at the nuclear periphery” Cell Reports, 2024

https://doi.org/10.1016/j.celrep.2024.114784

2024 ESMO (poster): Activity of ERK1/2 Inhibitor ASTX029 in Patients with Gynecological Malignancies Harboring Genomic Alterations in the MAPK Pathway

/in , , , , ,

View Poster:
2024 ESMO (poster): Activity of ERK1/2 Inhibitor ASTX029 in Patients with Gynecological Malignancies Harboring Genomic Alterations in the MAPK Pathway